The penny stock BVXV has exploded more than 16% higher in early trading on January 26, 2022, after Aegis initiated coverage of the stock with a Buy rating.
BiondVax initiated with a Buy at Aegis
Aegis analyst Nathan Weinstein initiated coverage of BiondVax with a Buy rating and $7 price target.
BiondVax to Present at Edison Group’s Open House Conference
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it is presenting at the Edison Open House: Global Healthcare 2022 conference.
BiondVax’s presentation is currently available on-demand via the conference portal at https://www.edisongroup.com/edison-open-house-global-healthcare-2022.
BiondVax’s management will also be meeting with investors in a virtual 1-1 setting in relation to this conference. If you wish to set up a meeting with management, please do so via the conference portal or speak directly with investor relations at BiondVax.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit https://www.biondvax.com.
Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
On January 3, 2022, Aegis Capital Corp. acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV).
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline.
Former CFO of GSK’s Global Vaccines Business Mr. Jay Green Joins BiondVax’s Board of Directors
On December 27, 2021, BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that all proposed resolutions were approved at today’s Annual General Meeting of Shareholders, including the election of Mr. Jay Green to the Company’s Board of Directors. Mr. Green recently completed a six-year term as Senior Vice President Finance and CFO of GlaxoSmithKline plc’s (NYSE: GSK) global vaccines business. Concurrently, Mr. Isaac Devash retired from the Board of Directors.
Mark Germain, BiondVax’s Chairman of the Board of Directors, stated, “We’re very excited to have Jay join our board of directors, particularly as we relaunch the company’s R&D efforts around the unique nanosized antibody (NanoAb) program in collaboration with the Max Planck Institute. Jay’s experience serving as GSK Vaccine’s SVP Finance/CFO and his current involvement in the global COVID–19 response as an advisor to Gavi for COVAX is highly relevant and adds a significant dimension to our Board. We aim to leverage his broad knowledge and deep connections as we progress in developing our NanoAbs program, beginning with a highly promising COVID-19 therapy.”
Continued Mr. Germain, “On a personal note, I wish to thank Isaac Devash for his many years of valued service to BiondVax. Isaac has been a dedicated leader on the board and instrumental and highly supportive in our efforts to relaunch the company. He remains a friend to the company and through our successful turnaround we intend to make him proud of the time and effort he has devoted.”
Jay Green commented, “I am pleased to join BiondVax as we begin work on the nanosized antibody (NanoAb) pipeline towards new and improved therapies for multiple diseases with substantial commercial potential. BiondVax is a company with significant opportunity, at a new and exciting inflection point, and I look forward to helping them deliver value to both patients and investors in the near and long term.”
Mr. Jay Green, CPA, CA, MAcc, recently completed a 19-year career with GSK across several progressive leadership positions in GSK’s three businesses of consumer healthcare, pharmaceuticals, and vaccines, as well as corporate development. He also led GSK’s global enterprise resource planning (ERP) program, one of the largest IT-enabled business transformation programs in the company’s history. Mr. Green most recently served from 2014 to 2020 as Senior Vice President, Finance and CFO of GSK’s global vaccines business. Since 2020, Mr. Green has served in an advisory role to Gavi for COVAX, an international initiative to support equitable distribution of COVID-19 vaccines. He is a Chartered Professional Accountant who holds a Master of Accounting from the University of Waterloo, Ontario, Canada.
BiondVax to partner with Max Planck Society on COVID-19 nanosized antibodies
On December 22, 2021, BiondVax Pharmaceuticals announced the signing of definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute of Biophysical Chemistry, and the University Medical Center Gottingen, both in Germany, to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies. These agreements are part of a broader collaboration, expected to be signed in January 2022, covering development and commercialization of NanoAbs for several other disease indications with large market sizes that leverage their unique binding affinity, stability at high temperatures, and potential for more effective and convenient routes of administration. In addition to the COVID-19 NanoAb collaboration and as previously announced, BiondVax, MPG and UMG have signed a term-sheet for development of NanoAbs towards other indications with major opportunities in key therapeutic areas of psoriasis, asthma, macular degeneration, and psoriatic arthritis. These are all diseases with known and validated antibody drug targets, and where the NanoAb advantages have the potential to capture significant market share. BiondVax anticipates finalizing the collaboration agreements for these additional NanoAbs in January 2022. BiondVax is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. In particular, NanoAbs can be mass-produced through recombinant protein manufacturing in sites such as BiondVax’s GMP biologics manufacturing facility in Jerusalem. BiondVax anticipates conducting COVID-19 NanoAb preclinical studies in 2022 with initial human clinical trials results in 2023.
📺 BiondVax: Who we are & Where we’re going[embedyt] https://www.youtube.com/watch?v=ETQ0tmcOtMo[/embedyt]
📉 BVXV Stock Technical Analysis
Both the long and short-term trends are negative. It is better to avoid buying stocks with negative trends. BVXV is part of the Pharmaceuticals industry. There are 267 other stocks in this industry, BVXV did better than 47% of them. BVXV is currently trading near the lower end of its 52-week range, which is not a good sign. BVXV is lagging the S&P500 Index which is trading in the middle of its 52-week range. Prices have been falling strongly lately, it is better to avoid new long positions here.
There is a resistance zone ranging from 1.88 to 1.90. This zone is formed by a combination of multiple trend lines and important moving averages in multiple time frames. There is resistance at 2.47 from a trend line in the weekly time frame. There is also resistance at 2.71 from a trend line in the weekly time frame. Finally, there is resistance at 2.81 from a trend line in the daily time frame.
The technical rating of BVXV is bad and it also does not present a quality setup at the moment. BVXV stock has a Setup Rating of 3 out of 10. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when BVXV consolidates and has a Setup Rating of 8 or higher.